Bempedoic Acid Cuts Stroke Risk by 22% – Esperion Study

Esperion Therapeutics announced new data on March 30, 2026, highlighting the cardiovascular benefits of bempedoic acid for high-risk patient populations. The biopharmaceutical company presented two post-hoc analyses from the CLEAR Outcomes clinical trial during the American College of Cardiology’s Annual Scientific Session. These sessions, designated as ACC.26, took place from March 28 to March 30, 2026, in New Orleans, Louisiana. The data focused on specific risks regarding ischemic stroke and major adverse cardiovascular events in patients with autoimmune or inflammatory diseases.

Reduced Risk of Ischemic Stroke

The primary analysis demonstrated a significant reduction in stroke risk for patients utilizing the therapy. According to the presentation, patients taking bempedoic acid showed a 22% reduced risk of ischemic stroke compared to those taking a placebo. This finding addresses a critical area of cardiovascular health, particularly for individuals who face elevated risks due to existing conditions or intolerance to other treatments.

The data reinforces the potential utility of the therapy for statin-intolerant patients. When examining ischemic stroke patients specifically, the analysis indicated a clear and clinically relevant reduction in risk. This distinction is vital for clinical decision-making regarding lipid-lowering strategies in vulnerable groups who may not tolerate standard statin therapy.

Impact on Patients with Autoimmune Diseases

The second post-hoc analysis from the CLEAR Outcomes trial examined patients with autoimmune or inflammatory diseases. These conditions often contribute to a significantly elevated cardiovascular burden. The report indicated that bempedoic acid reduced major adverse cardiovascular events, known as MACE, in high-risk patients with autoimmune or inflammatory diseases similarly to those without these conditions.

This consistency suggests that the therapy delivers meaningful reductions in cardiovascular events across diverse patient populations. The CLEAR Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovascular disease. These specific sub-analyses provide deeper understanding into how the drug performs within complex medical profiles.

Expert Commentary on Clinical Value

Luke Laffin, MD, served as the senior author of the CLEAR Outcomes sub analyses. He is an Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Laffin emphasized the importance of these findings for vulnerable groups facing higher cardiovascular burdens.

These analyses provide important insights into how bempedoic acid performs in high-risk patient populations. Patients with autoimmune and inflammatory diseases face a significantly elevated cardiovascular burden, and these data reinforce that bempedoic acid delivers meaningful reductions in cardiovascular events in this vulnerable group. When we examine ischemic stroke patients specifically, this analysis shows a clear and clinically relevant reduction in risk for statin intolerant patients. Together, these findings underscore the value of bempedoic acid as an effective, well tolerated therapy for reducing cardiovascular risk across diverse patient populations.

Luke Laffin, MD, Cleveland Clinic Lerner College of Medicine

Company Perspective on Evidence Base

Sheldon Koenig, President and Chief Executive Officer of Esperion, commented on the strengthening evidence surrounding the therapy. The company, traded on NASDAQ under the ticker ESPR, views these analyses as further validation for their flagship product, NEXLETOL. The announcement originated from Ann Arbor, Michigan, on March 30, 2026.

These new analyses from CLEAR Outcomes further strengthen the evidence base supporting NEXLETOL as a proven therapy for cardiovascular risk reduction – especially for patients who cannot tolerate statin therapy.

Sheldon Koenig, President and CEO of Esperion

Recent Guideline Inclusions

This presentation follows recent developments regarding the regulatory and guideline status of bempedoic acid. On March 16, 2026, Esperion welcomed the inclusion of bempedoic acid for LDL-C lowering in multiple Class 1 recommendations. These updates occurred shortly before the ACC.26 scientific session, providing a broader context for the new clinical data presented in New Orleans.

The combination of guideline updates and new outcome data suggests a growing consensus on the role of ATP citrate lyase inhibitors in cardiovascular care. The CLEAR Outcomes trial continues to serve as a primary source of evidence for these developments. Further research into the total burden of cardiovascular events remains a key point of investigation for medical institutions and regulators monitoring lipid-lowering regimens.

The data presented at ACC.26 contributes to the ongoing evaluation of cardiovascular risk reduction strategies. By focusing on specific subgroups such as those with autoimmune diseases or statin intolerance, the analyses offer targeted insights for clinicians managing high-risk patients. The findings support the use of bempedoic acid as part of a comprehensive approach to reducing major adverse cardiovascular events.